Narcolepsy Products Prior Authorization Policy
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements for Wakix, sodium oxybate products (Xyrem, Xywav, Lumryz) for narcolepsy and related indications; applies to pharmacy benefit coverage decisions for members under Medical Mutual - Ohio.
No material clinical or coverage changes in this revision.
Coverage Criteria for Narcolepsy Products
Wakix — Excessive Daytime Sleepiness (EDS) with Narcolepsy
Covered when ALL of the following are met:
Concomitant use of sodium oxybate products is not recommended. Specifically, Lumryz, sodium oxybate oral solution (Xyrem), and Xywav should not be used together or alternated because they contain the same active moiety (oxybate) and have not been studied in combination. Additionally, use of any oxybate product in combination with Wakix (pitolisant) or Sunosi (solriamfetol) is not recommended due to lack of published evidence evaluating such combinations and potential safety concerns related to combining a CNS depressant with other wake-promoting agents.
Long‑term maintenance treatment of fibromyalgia with sodium oxybate products is not recommended. An FDA advisory panel previously rejected approval of Xyrem for fibromyalgia based on trials that failed to show significant efficacy versus existing fibromyalgia therapies and concerns about limited information on drug interactions; therefore chronic use for this indication lacks supporting evidence.
Coverage is not recommended for uses or situations that are not explicitly listed in the Recommended Authorization Criteria. The policy will be updated if new published data support additional indications, but until then requests outside the specified criteria should be denied as not meeting medical necessity.
Wakix, sodium oxybate oral solution (Xyrem), Lumryz, and Xywav are not recommended for certain conditions because evidence is insufficient or safety concerns exist. Examples include long‑term maintenance therapy for fibromyalgia (Xyrem, Lumryz, Xywav) and other unlisted indications where clinical benefit has not been established. The policy notes that these products have limited or preliminary data for such conditions and that the list of non‑recommended conditions is not exhaustive.
Impacted Drugs, Age Criteria, and Codes
| Wakix | pitolisant tablets |
| Xyrem | sodium oxybate oral solution |
| Xywav | calcium, magnesium, potassium, and sodium oxybates oral solution |
| Lumryz | sodium oxybate extended-release oral suspension |
| Wakix | pitolisant tablets - Harmony |
| Xyrem | sodium oxybate oral solution - Jazz, generic |
| Xywav | calcium, magnesium, potassium, and sodium oxybates oral solution - Jazz |
| Lumryz | sodium oxybate extended-release oral suspension - Avadel |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required for the listed narcolepsy products prior to pharmacy benefit coverage. Initial approvals require the drug be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted in the policy; reauthorization requires documented response to therapy when continuation is allowed.
- Affected products: Wakix (pitolisant), Xyrem (sodium oxybate), Xywav (mixed-cation oxybate), Lumryz (sodium oxybate ER).
- Prescriber requirement: prescribed by or in consultation with a sleep disorder specialist, neurologist, pulmonologist, or psychiatrist as specified per criteria.
Step-Therapy / Multiple-Step Requirements
Step-therapy and multiple-step requirements apply and vary by product and indication. For EDS and cataplexy criteria, trials of modafinil or armodafinil, or trials of CNS stimulants (e.g., methylphenidate, dexmethylphenidate, dextroamphetamine) are required per the specific product/age/indication rules. For some adult EDS criteria additional prior trials may include Lumryz, Sunosi, and Wakix or documented contraindications/intolerance to those agents.
- Examples: adults may need trials of two agents from CNS stimulant/modafinil/armodafinil; pediatric criteria may require one trial depending on age and indication.
- For idiopathic hypersomnia (Xywav) the patient must have tried at least one of modafinil, armodafinil, or methylphenidate.
Documentation May Be Requested
The Company may request additional documentation to support medical necessity as part of its coverage determination.
- Documentation may include patient medical records, polysomnography and multiple sleep latency test (MSLT) results, and provider credentials.
- Be prepared to supply requested records promptly to avoid delays or adverse coverage determinations.
Denial Risk for Insufficient Criteria or Documentation
The Company may deny reimbursement when coverage criteria are not met or documentation is insufficient.
- Denial reasons include: drug or service not medically necessary, investigational or experimental, not within the member's benefits, or inappropriate/excessive billing patterns.
- Ensure submitted documentation demonstrates medical necessity and meets the policy's diagnostic and prior-trial requirements to reduce denial risk.
Background and Clinical Context
Wakix (pitolisant) is a non‑controlled histamine‑3 (H3) receptor antagonist/inverse agonist indicated for treatment of excessive daytime sleepiness (EDS) and for reduction of cataplexy in narcolepsy. Sodium oxybate products (Xyrem, Xywav, Lumryz) are formulations of oxybate, a CNS depressant indicated for EDS and cataplexy in narcolepsy (age thresholds vary by product), and Xywav additionally has an indication for idiopathic hypersomnia in adults. Diagnosis confirmation for these disorders commonly requires polysomnography and multiple sleep latency testing, and prior authorization is required for these agents with initiation by or in consultation with a sleep specialist or neurologist per the policy.
Key Definitions
Revision History
Policy last revised; document lists Last Revised Date as 03/19/2026.
Annual review date / next scheduled review is 08/21/2025 as listed in the policy header.
References accessed/updated (e.g., NIH narcolepsy page and AASM guidance) on June 24, 2024 per reference citations.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.